Career history of William T. Andrews
Former positions of William T. Andrews
Companies | Position | Start | End |
---|---|---|---|
FLEXION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2021 | 19/11/2021 |
ACER THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 05/10/2017 | 08/07/2020 |
AEGERION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2012 | 01/05/2014 |
Corporate Officer/Principal | 01/05/2014 | 01/01/2016 | |
AKCEA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 09/07/2020 | - |
Training of William T. Andrews
Harvard University | Undergraduate Degree |
Yale School of Medicine | Doctorate Degree |
Statistics
International
United States | 7 |
Operational
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 4 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
- Stock Market
- Insiders
- William T. Andrews
- Experience